515 related articles for article (PubMed ID: 29788127)
21. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
22. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
23. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Bressler B; Francisconi C; Vermeire S; Lawendy N; Salese L; Sawyerr G; Shi H; Su C; Judd DT; Jones T; Loftus EV
Inflamm Bowel Dis; 2023 Jan; 29(1):27-41. PubMed ID: 36342120
[TBL] [Abstract][Full Text] [Related]
25. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
[TBL] [Abstract][Full Text] [Related]
27. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Huang F; Luo ZC
Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
[TBL] [Abstract][Full Text] [Related]
29. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea.
Kim YE; Kim YJ; Jeong DH; Kim S; Kim MJ; Kim HH; Jo KW; Park SH; Hong S
Semin Arthritis Rheum; 2024 Apr; 65():152362. PubMed ID: 38281468
[TBL] [Abstract][Full Text] [Related]
30. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
31. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
32. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
[TBL] [Abstract][Full Text] [Related]
33. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
34. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
Palasik BN; Wang H
J Pharm Pract; 2021 Dec; 34(6):913-921. PubMed ID: 32873116
[TBL] [Abstract][Full Text] [Related]
35. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Noell C; Arbeit R; Kanhoush R
Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
[TBL] [Abstract][Full Text] [Related]
36. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
37. Herpes zoster in psoriasis patients treated with tofacitinib.
Winthrop KL; Lebwohl M; Cohen AD; Weinberg JM; Tyring SK; Rottinghaus ST; Gupta P; Ito K; Tan H; Kaur M; Egeberg A; Mallbris L; Valdez H
J Am Acad Dermatol; 2017 Aug; 77(2):302-309. PubMed ID: 28711084
[TBL] [Abstract][Full Text] [Related]
38. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
[TBL] [Abstract][Full Text] [Related]
39. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Winthrop KL; Nash P; Yamaoka K; Mysler E; Khan N; Camp HS; Song Y; Suboticki JL; Curtis JR
Ann Rheum Dis; 2022 Feb; 81(2):206-213. PubMed ID: 34615638
[TBL] [Abstract][Full Text] [Related]
40. [JAK Inhibitors in Rheumatology].
Witte T
Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
